Articles liés

Garetosmab (Pasatru)

Monoclonal antibody marketed as Pasatru by Regeneron; reported to reduce new abnormal bone formation by 90 percent in F.O.P.

• De nouveaux traitements offrent de l'espoir aux patients atteints du trouble osseux incontrôlable F.O.P.